Amarin Regains Compliance With Nasdaq Listing Re...( LONDON February 11 /- Amarin Corp...),Health

LONDON, February 11 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRND) today announced that it has received notification from The Nasdaq Stock Market that the Company has regained compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market, pursuant to Nasdaq Marketplace Rule 4320(e)(2)(E)(ii). In the notification, Nasdaq advised that the Company has regained compliance with all continued listing requirements and that this matter is now closed.

Thomas Lynch, Chairman and Chief Executive Officer, commented "We are pleased to receive this notification, as continued listing on Nasdaq is an integral part of our plans to build shareholder value, having recently expanded our pipeline and strengthened our management team."

About Amarin

Amarin is committed to improving the lives of patients suffering from central nervous system (CNS) and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technol
'/>"/>